Kelsey Holzer, APRN
Family · Mandan, NDNPI 1760051601
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 253 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $15.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$791
- AbbVie$587
- Amgen$549
- Lilly USA, LLC$545
- Novo Nordisk$305
- Boehringer Ingelheim$217
- plus $936 from 18 others
What the payments were for
- Food & beverage$3,929100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $791 |
| AbbVie | 48 | $587 |
| Amgen | 43 | $549 |
| Lilly USA, LLC | 44 | $545 |
| Novo Nordisk | 37 | $305 |
| Boehringer Ingelheim | 17 | $217 |
| Pfizer | 11 | $167 |
| Merck | 8 | $152 |
| Astellas Pharma US Inc | 5 | $115 |
| Novartis | 4 | $65 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $54 |
| Actelion Pharmaceuticals US, Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Bayer | 2 | $33 |
| GSK | 2 | $31 |
| Johnson & Johnson | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 2 | $24 |
| Phadia US Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Alkermes, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,929 in reported general payments places this provider in the 95th percentile of 496 family providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 56 | $28,808 |
| EliquisApixaban | 21 | $18,792 |
| JardianceEmpagliflozin | 13 | $15,311 |
| XareltoRivaroxaban | 27 | $15,146 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $12,715 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $9,121 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $3,414 |
| Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc | 27 | $2,720 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $1,599 |
| Levothyroxine Sodium | 90 | $1,423 |
| Rosuvastatin Calcium | 117 | $1,312 |
| Atorvastatin Calcium | 141 | $1,270 |
| Omeprazole | 106 | $1,218 |
| Pantoprazole Sodium | 119 | $1,145 |
| Celecoxib | 19 | $986 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $791 | $28,80856 claims |
| PfizerEliquis | $167 | $18,79221 claims |
| Boehringer IngelheimJardiance | $217 | $15,31113 claims |
| Johnson & JohnsonXarelto | $29 | $15,14627 claims |
| GSKTrelegy Ellipta | $31 | $9,12114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 family providers in North Dakota.
Other family in Mandan
- Joshua HadsellMandan$2K
- Jenna MeldahlMandan$2K
- Cortney KahlMandan$2K
- Christina DahlJamestown$26K
- Coralyn Jensen KurtzGrand Forks$12K
- Paula RickeGrand Forks$9K
- Courtney WoodburyBismarck$8K
- Monica GoetzBismarck$8K
- Danielle EidenschinkFargo$6K
- Chantel HillestadMinot$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.